Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Mi | EC's von der Leyen loses bid to stop disclosure of Pfizer texts | ||
Mi | Novo makes fresh obesity play with $2.2bn Septerna deal | ||
Mi | GSK pays $1.2bn for liver drug as it culls TIGIT programme | ||
Mi | Call goes out for feedback on US health deregulation | ||
Mi | UnitedHealth CEO Andrew Witty steps down | ||
Mi | UnitedHealth CEO Chris Witty steps down | ||
Di | Digital support reduces GLP-1 dose needed for weight loss | ||
Di | Bayer CEO confident firm can cope with Xarelto hit | ||
Di | Galapagos drops plan to split after 'market developments' | ||
Di | Azafaros bags €132m for rare neuro-metabolic disorder drugs | ||
Di | Novo Nordisk builds case for Norditropin successor | ||
Mo | Digital therapy for Tourette syndrome backed for NHS use | ||
Mo | UK approves AZ inhaler with 'greener' propellant | ||
Mo | Could an AI for biological age guide cancer treatment? | ||
Mo | More data backs Zepbound over Wegovy for weight loss | ||
Mo | More data back Zepbound over Wegovy for weight loss | ||
Mo | Trump says he will tie US drug prices to other countries | ||
Fr | Vor Bio winding down as multiple biotechs downsize | ||
Fr | GSK reveals data behind linerixibat for PBC 'relentless itch' | ||
Fr | AZ plots wider Imfinzi use in bladder cancer after trial win | ||
Fr | Pharma still in waiting mode after UK-US trade agreement | ||
08.05. | FDA announces generative AI pilot and rapid rollout plans | ||
08.05. | Boehringer advances oral therapy for geographic atrophy | ||
08.05. | Gilead ups its US investment plans by $11 billion | ||
08.05. | Spectre of 'favoured nation' pricing manifests again in US |